Text Size

A post-marketing surveillance of 0.5% levofloxacin ophthalmic solution for external ocular infections

Kanda Y., Kayama T., Okamoto S., Hashimoto M., Ishida C., Yanai T., Fukumoto M., Kunihiro E.

  • 2008
  • Japanese Journal of Clinical Ophthalmology
View publication
  • Therapeutic Area


  • Categories

    Preclinical development

  • Affiliations

    PMS Group, Santen Pharmaceutical Co Ltd, Japan; Drug Safety Information Group, Santen Pharmaceutical Co Ltd, Japan; Post-Marketing Surveillance Group, Santen Pharmaceutical Co., Ltd., 3-9-19 Shimo-Shinjo, Osaka 533-8651, Japan

Related Publications

Viability of European cross-border access opportunities to streamline access to ATMPs

Angelillo L.; van Steen C.; Ross-Stewart K.; Dehnen J.; Colasante W.

Influence of BAKs on Tear Film Lipid Layer: in vitro and in silico models

Riedlová K., Saija M.C., Olżyńska A., Jurkiewicz P., Daull P., Garrigue J.-S., Cwiklik L.

How Useful Are Digital Health Terms for Outcomes Research? An ISPOR Special Interest Group Report

Burrell, Anita; Zrubka, Zsombor; Champion, Annette; Zah, Vladimir; Vinuesa, Laura; Holtorf, Anke-Peggy; Di Bidino, Rosella; Earla, Jagadeswara Rao; Entwistle, Joanna; Boltyenkov, Artem Tarasovic; Braileanu, George; Kolasa, Katarzyna; Roydhouse, Jessica; Asche, Carl

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022